CAM2029, a self-administered subcutaneous octreotide depot, improved PROs and symptoms in patients with acromegaly in the ACROINNOVA 2 Phase 3 trial: final analysis of the core phase results

Somatuline Depot (lanreotide prolonged-release subcutaneous) - Ipsen

Oclaiz (octreotide subcutaneous depot) - Camurus

octreotide acetate - Generic mfg.

https://ese-hormonesdistribute.m-anage.com/from.storage?image=q5B08HqJEWT974SjeAc7Jnscv0hIVWBRM8pq_9-KKK3dlrRSE-WPqgS1RCIWdcN30

Diego Ferone * 1; Beverly M.K. Biller 2; Monica R. Gadelha 3; Julie M. Silverstein 4; Pinar Kadioglu 5; Jochen Seufert 6; Maria Fleseriu 7; Alberto M. Pedroncelli 8; Jacob Råstam 8; Maria Harrie 8; Agneta Svedberg 8; Fredrik Tiberg 8; Joanna L. Spencer-Segal 9

Apr 10, 2025